ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
06 févr. 2024 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling
29 janv. 2024 12h05 HE
|
Doheny Eye Institute
PASADENA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, is pleased to announce the publication of important new findings...
Global Diabetic Retinopathy Market Size, Share & Trends Analysis Report 2024-2030: Non-Proliferative Diabetic Retinopathy Accounted for the Largest Share, By Type in 2023
24 janv. 2024 05h35 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative DR, Non-Proliferative DR), Management (Anti-VEGF...
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
23 janv. 2024 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
21 déc. 2023 05h50 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
04 déc. 2023 14h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS
DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
01 déc. 2023 12h32 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
28 nov. 2023 16h01 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM
TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
09 nov. 2023 12h58 HE
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration
and Alzheimer’s Syndrome.
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
08 nov. 2023 05h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE